Price History
Investment Checklist
Technical Analysis
Technical Analysis
Analysis from 2026-07-10
Trend
Price below most MAs — downtrend | Bullish MA stack (20>50>200)
Price Action
Support & Resistance Levels
Volume Analysis
Recent MA Crossovers
Recent Price Gaps
Stop Loss Levels
Fixed Risk
Technical Levels
Financials
Financial Analysis
| Metric | Mar '25 | Jun '25 | Sep '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹8,506 Cr | ₹8,545.2 Cr | ₹8,805.1 Cr | ₹8,726.8 Cr |
| Net Profit | ₹1,593.8 Cr | ₹1,417.8 Cr | ₹1,437.2 Cr | ₹1,209.8 Cr |
| EPS | ₹19.12 | ₹17.04 | — | ₹14.53 |
| Operating Profit | ₹2,526.4 Cr | ₹2,464.2 Cr | ₹2,430.8 Cr | ₹2,158.6 Cr |
Peer Comparison
PharmaceuticalsPeer Comparison
Symbol | Name | Price | Change | P/E Ratio | Market Cap |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,935.50 | -0.17% | 40.2 | ₹4.64L Cr large Cap | |
| Divi's Laboratories Limited | ₹6,836.00 | +0.34% | 70.4 | ₹1.81L Cr large Cap | |
| Torrent Pharmaceuticals Limited | ₹4,901.50 | +0.07% | 77.5 | ₹1.66L Cr large Cap | |
| Cipla Limited | ₹1,439.40 | -0.13% | 30.1 | ₹1.16L Cr large Cap | |
| Zydus Lifesciences Limited | ₹1,150.80 | -0.71% | 23.0 | ₹1.16L Cr large Cap | |
| Lupin Limited | ₹2,496.30 | -0.28% | 21.4 | ₹1.14L Cr mid Cap | |
| Mankind Pharma Limited | ₹2,525.10 | -0.27% | 54.3 | ₹1.04L Cr mid Cap | |
| Dr. Reddy's Laboratories Limited | ₹1,244.30 | -1.99% | 25.6 | ₹1.04L Cr large Cap | |
| Aurobindo Pharma Limited | ₹1,564.70 | -1.43% | 26.1 | ₹90.88K Cr mid Cap | |
| Laurus Labs Limited | ₹1,537.80 | +2.02% | 91.5 | ₹83.02K Cr mid Cap | |
| Biocon Limited | ₹418.50 | +3.70% | 177.4 | ₹67.83K Cr mid Cap |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 10 Jul 2026 | Dividend - Rs 8 Per Share | DIVIDEND |
| 10 Jul 2025 | Dividend - Rs 8 Per Share | DIVIDEND |
| 28 Oct 2024 | Face Value Split (Sub-Division) - From Rs 5/- Per Share To Re 1/- Per Share | STOCK_SPLIT |
| 16 Jul 2024 | Annual General Meeting/Dividend - Rs 40 Per Share | AGM |
| 11 Jul 2023 | Annual General Meeting/Dividend - Rs 40 Per Share | AGM |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
| Date | Purpose | Type |
|---|---|---|
| 22 Jul 2026 | Financial Results | RESULTS |
Latest News
News for DRREDDY
View All
Dr Reddy's shares crash 9% in 2 days; brokerages slash target prices after semaglutide supply disruption. What lies ahead?
Dr Reddy's Laboratories shares extended their decline after the company delayed commercial supplies of its semaglutide product due to a quality-related API issue. While brokerages remain broadly positive on the long-term outlook, several have cut target prices and earnings estimates, citing near-term execution risks and slower product ramp-up.
Dr Reddy’s pauses weight loss drug on quality fears
Dr Reddy's Laboratories will halt semaglutide injection supplies until at least October. Unspecified impurities were identified during the active pharmaceutical ingredient manufacturing scale-up. The company assures that already supplied market products remain safe for patient use. Torrent Pharmaceuticals and USV Ltd are recalling some semaglutide batches sourced from Dr Reddy's. Commercial supplies are expected to resume after the issue is resolved and validation is complete.
Torrent recalls select Semalix diabetes injection pens after Dr Reddy's flags quality issue
The recall affects only select 2 mg and 4 mg Semalix injection pens manufactured by Dr Reddy's Laboratories, while all other semaglutide products remain unaffected.